ClinicalTrials.gg
CompletedNCT05110638Updated Aug 21, 2026

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis

A Phase 1 interventional study of SKX-16 (Luliconazole 10% Solution) in Onychomycosis of Toenail, sponsored by SATO Pharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by SATO Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.

Enrollment
62nd of 75
19 · median 50
Started
2021
with 1 other
Phase 1
11 of 77
none open now
Registered
68th of 77
by date

Among the 77 studies in Onychomycosis with a site in United States, this one is the 62nd largest by enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 in phase 1, and was the 68th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Onychomycosis with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to determine the pharmacokinetics, systemic exposure, safety and tolerability after daily topical application of SKX-16 (Luliconazole 10% Solution) for duration of 29 days in a maximal use setting in adults with moderate to severe distal subungual onychomycosis of the toenails.

Read the detailed description

Subjects in this open-label study will receive once daily, topical applications of SKX-16 (Luliconazole 10% Solution) in the clinic for 29 days. Subjects will be followed for seven days after the last application (Day 29).

Subjects will be admitted into the study after written informed consent has been obtained and all inclusion/exclusion criteria have been met.

03

Conditions studied

  • Onychomycosis of Toenail

Browse trials for

Keywords

  • Onychomycosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects demonstrate ability and willingness to sign a written .
  2. Subjects of either gender, any race and between the ages of 18 and 65 inclusive.
  3. Subjects must have ten toes.
  4. Subjects with a clinical diagnosis of distal subungual onychomycosis involving both great toenails and ≥ 50% of at least one of the great toenails, as determined by visual inspection after the nail is trimmed.
  5. In addition to both great toenails, subjects must have at least four additional toenails with clinical diagnosis of distal subungual onychomycosis.
  6. Subjects must have a mycological diagnosis of distal subungual onychomycosis: fungal hyphae on KOH wet mount and positive fungal culture for dermatophyte (microbial infection with fungus belonging to the genus Trichophyton, Microsporum, Epidermophyton) from at least one great toenail.
  7. Subjects must have normal renal function as measured by serum creatinine \< .
  8. Subjects must have normal hepatic function as measured by (AST/SGOT), alanine aminotransferase (ALT/SGPT), and total \< ULN.
  9. Females of (FOCBP) must have a negative urine pregnancy test and must agree to use a highly effective form of or abstinence and be willing to remain on that same method of birth control throughout the study.
  10. Subjects must be free of any disease that in the Investigator's opinion might interfere with the study evaluations or jeopardize the subject's safety.
  11. Subject must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of intolerance or to imidazole compounds or the inactive components of the solution.
  2. Subjects with an abnormal morphology and/or a interval > 450 ms for males and >470 ms for females.
  3. Subjects with any history of cardiac disease or cardiac rhythm abnormalities.
  4. Subjects with symptomatic tinea pedis at baseline.
  5. Subjects unwilling to refrain from the use of nail cosmetics including nail lacquers from the Screening visit until the end of the study.
  6. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial.
  7. Concomitant use of any drugs that are and CYP2C19 substrates with QT interval prolongation potential.
  8. Subjects who have not undergone the specified (s) prior to Baseline visit (Day 1) for the following topical preparations, or subjects requiring the concurrent use of any of the following topical medications: Topical antifungal applied to the feet, drugs that contain luliconazole, anti-inflammatories, or topical immunomodulators.
  9. Systemic antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes within the previous 12 weeks or 5 half-lives of the drug, whichever is longer.
  10. Subjects who have not undergone the specified washout period(s) prior to Baseline (Day 1) for the following systemic medications, or subjects requiring the concurrent use of any of the following systemic medications: Corticosteroids (including intramuscular injections), systemic immunomodulators and drugs that are CYP3A and CYP2C19 substrates
  11. Subjects receiving any other treatment/therapy for their onychomycosis not previously mentioned (e.g., laser treatment) who have not undergone a washout period of 4 weeks.
  12. Subjects with a history of significant internal disease (including diabetes that is uncontrolled), history or signs of peripheral circulatory insufficiency and/or diabetic neuropathy, recurrent cellulitis or with a life-threatening condition (e.g., deficiency syndrome, cancer, unstable angina, or myocardial infarction) as assessed by the Investigator within the last 6 months.
  13. Subjects with anatomic abnormalities of the toe(s) and/or toenails, e.g., genetic nail disorders, trauma to the toenail(s).
  14. Subjects with a recent history of or currently known to abuse drugs or alcohol.
  15. Subjects who have donated or lost a large volume of blood (\~500 mL or more), during the 6-week period preceding Baseline visit (Day 1).
  16. Subjects who are currently participating in another medication or device study or have participated in a clinical trial within 30 days or 5 half-lives of the test medication (whichever is longer) prior to Baseline visit (Day 1) of this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    SKX-16 (Luliconazole 10% Solution)

    Drug: SKX-16 (Luliconazole 10% Solution)

Interventions

  • SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.

06

What researchers measure

Primary outcomes

  1. PK parameters for the systemic absorption of luliconazole - AUC0-24h

    The pharmacokinetics parameter AUC0-24h (the area under the concentration versus time curve measured to the 24 hour time point) will be measured for systemic absorption of luliconazole

    Time frame: 36 days

  2. PK parameters for the systemic absorption of luliconazole - AUC0-∞

    The pharmacokinetics parameter AUC0-∞ (the area under the concentration versus time curve measured to the end of the sampling period) will be measured for systemic absorption of luliconazole.

    Time frame: 36 days

  3. PK parameters for the systemic absorption of luliconazole - Cmax

    The pharmacokinetics parameter Cmax (the maximum observed concentration over the 0-24 hour interval) will be measured for systemic absorption of luliconazole.

    Time frame: 36 days

  4. PK parameters for the systemic absorption of luliconazole - Tmax

    The pharmacokinetics parameter Tmax (the time to maximum observed concentration over the 0-24 hour interval) will be measured for systemic absorption of luliconazole.

    Time frame: 36 days

  5. PK parameters for the systemic absorption of luliconazole - t1/2

    The pharmacokinetics parameter t1/2 (the time to maximum observed concentration over the 0-24 hour interval) will be measured for systemic absorption of luliconazole.

    Time frame: 36 days

  6. PK parameters for the systemic absorption of luliconazole - kel

    The pharmacokinetics parameter kel (elimination rate constant) will be measured for systemic absorption of luliconazole.

    Time frame: 36 days

  7. Safety Assessment - Local Application Site Tolerability Assessment (LASTA)

    Evaluation of burning/stinging, pruritus, erythema, and erosion assessed through to Day 29/ET on a scale of 0 to 3 where 0 indicates none and 3 indicates severe.

    Time frame: 36 days

  8. Safety Assessment - Adverse Events

    Subjects will be asked about AEs at each visit; descriptions of AEs will include at minimum: date of onset, date ended, location (whether or not AE is in the treatment area), severity, seriousness, relationship to study drug, and outcome.

    Time frame: 36 days

07

Study locations

1 site
  • J&S Studies, Inc.
    College Station, Texas 77845, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in May 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2021
First posted
Nov 8, 2021
StartActual
Sep 22, 2021
Primary completionActual
May 30, 2022
CompletionActual
Jun 6, 2022
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05110638
Lead sponsor
SATO Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Sep 22, 2021
Primary completion
May 30, 2022
Completion
Jun 6, 2022
Last update
Aug 21, 2026

Study contacts

Brent Clary, CCRC
study chair · Clinical Research Coordinator J&S Studies, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luliconazole

Start the discussion